Clinical trial
Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart…
NCT00086086 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00086086 |
|---|---|
| Title | Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia |
| Official title | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Effects of Treatment With 2 Regimens of Subcutaneous Darbepoetin Alfa (Weight-based Dosing and Fixed Dosing) on Hemoglobin Concentration Response in Subjects With Symptomatic CHF and Anaemia |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Congestive Heart Failure, Anemia |
| Intervention type | Drug |
| Interventions | Darbepoetin Alfa |
| Enrollment | 150 |
| Start date | Aug 1, 2003 |
| First posted | Jun 24, 2004 |
| Last update posted | Feb 9, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: